Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells

Gábor Petovári, Zoltán Hujber, Ildikó Krencz, Titanilla Dankó, Noémi Nagy, Fanni Tóth, Regina Raffay, Katalin Mészáros, Hajnalka Rajnai, Eniko Vetlényi, K. Takács-Vellai, A. Jeney, A. Sebestyén

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Glioma is the most common highly aggressive, primary adult brain tumour. Clinical data show that therapeutic approaches cannot reach the expectations in patients, thus gliomas are mainly incurable diseases. Tumour cells can adapt rapidly to alterations during therapeutic treatments related to their metabolic rewiring and profound heterogeneity in tissue environment. Renewed interests aim to develop effective treatments targeting angiogenesis, kinase activity and/or cellular metabolism. mTOR (mammalian target of rapamycin), whose hyper-activation is characteristic for many tumours, promotes metabolic alterations, macromolecule biosynthesis, cellular growth and survival. Unfortunately, mTOR inhibitors with their lower toxicity have not resulted in appreciable survival benefit. Analysing mTOR inhibitor sensitivity, other metabolism targeting treatments and their combinations could help to find potential agents and biomarkers for therapeutic development in glioma patients. Methods: In vitro proliferation assays, protein expression and metabolite concentration analyses were used to study the effects of mTOR inhibitors, other metabolic treatments and their combinations in glioma cell lines. Furthermore, mTOR activity and cellular metabolism related protein expression patterns were also investigated by immunohistochemistry in human biopsies. Temozolomide and/or rapamycin treatments altered the expressions of enzymes related to lipid synthesis, glycolysis and mitochondrial functions as consequences of metabolic adaptation; therefore, other anti-metabolic drugs (chloroquine, etomoxir, doxycycline) were combined in vitro. Results: Our results suggest that co-targeting metabolic pathways had tumour cell dependent additive/synergistic effects related to mTOR and metabolic protein expression patterns cell line dependently. Drug combinations, especially rapamycin + doxycycline may have promising anti-tumour effect in gliomas. Additionally, our immunohistochemistry results suggest that metabolic and mTOR activity alterations are not related to the recent glioma classification, and these protein expression profiles show individual differences in patients' materials. Conclusions: Based on these, combinations of different new/old drugs targeting cellular metabolism could be promising to inhibit high adaptation capacity of tumour cells depending on their metabolic shifts. Relating to this, such a development of current therapy needs to find special biomarkers to characterise metabolic heterogeneity of gliomas.

Original languageEnglish
Article number211
JournalCancer Cell International
Volume18
Issue number1
DOIs
Publication statusPublished - Dec 19 2018

Fingerprint

Doxycycline
Sirolimus
Glioma
Neoplasms
Therapeutics
temozolomide
Biomarkers
Immunohistochemistry
TOR Serine-Threonine Kinases
Cell Line
Proteins
Survival
Chloroquine
Glycolysis
Drug Combinations
Drug Delivery Systems
Metabolic Networks and Pathways
Individuality
Brain Neoplasms
Phosphotransferases

Keywords

  • Anti-metabolic drug combinations
  • Doxycycline
  • Glioblastoma
  • mTOR inhibitor
  • Rapamycin
  • Temozolomide
  • Tumour metabolism

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells. / Petovári, Gábor; Hujber, Zoltán; Krencz, Ildikó; Dankó, Titanilla; Nagy, Noémi; Tóth, Fanni; Raffay, Regina; Mészáros, Katalin; Rajnai, Hajnalka; Vetlényi, Eniko; Takács-Vellai, K.; Jeney, A.; Sebestyén, A.

In: Cancer Cell International, Vol. 18, No. 1, 211, 19.12.2018.

Research output: Contribution to journalArticle

Petovári, Gábor ; Hujber, Zoltán ; Krencz, Ildikó ; Dankó, Titanilla ; Nagy, Noémi ; Tóth, Fanni ; Raffay, Regina ; Mészáros, Katalin ; Rajnai, Hajnalka ; Vetlényi, Eniko ; Takács-Vellai, K. ; Jeney, A. ; Sebestyén, A. / Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells. In: Cancer Cell International. 2018 ; Vol. 18, No. 1.
@article{7dd1717b04c74a3dab342cfc235326d2,
title = "Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells",
abstract = "Background: Glioma is the most common highly aggressive, primary adult brain tumour. Clinical data show that therapeutic approaches cannot reach the expectations in patients, thus gliomas are mainly incurable diseases. Tumour cells can adapt rapidly to alterations during therapeutic treatments related to their metabolic rewiring and profound heterogeneity in tissue environment. Renewed interests aim to develop effective treatments targeting angiogenesis, kinase activity and/or cellular metabolism. mTOR (mammalian target of rapamycin), whose hyper-activation is characteristic for many tumours, promotes metabolic alterations, macromolecule biosynthesis, cellular growth and survival. Unfortunately, mTOR inhibitors with their lower toxicity have not resulted in appreciable survival benefit. Analysing mTOR inhibitor sensitivity, other metabolism targeting treatments and their combinations could help to find potential agents and biomarkers for therapeutic development in glioma patients. Methods: In vitro proliferation assays, protein expression and metabolite concentration analyses were used to study the effects of mTOR inhibitors, other metabolic treatments and their combinations in glioma cell lines. Furthermore, mTOR activity and cellular metabolism related protein expression patterns were also investigated by immunohistochemistry in human biopsies. Temozolomide and/or rapamycin treatments altered the expressions of enzymes related to lipid synthesis, glycolysis and mitochondrial functions as consequences of metabolic adaptation; therefore, other anti-metabolic drugs (chloroquine, etomoxir, doxycycline) were combined in vitro. Results: Our results suggest that co-targeting metabolic pathways had tumour cell dependent additive/synergistic effects related to mTOR and metabolic protein expression patterns cell line dependently. Drug combinations, especially rapamycin + doxycycline may have promising anti-tumour effect in gliomas. Additionally, our immunohistochemistry results suggest that metabolic and mTOR activity alterations are not related to the recent glioma classification, and these protein expression profiles show individual differences in patients' materials. Conclusions: Based on these, combinations of different new/old drugs targeting cellular metabolism could be promising to inhibit high adaptation capacity of tumour cells depending on their metabolic shifts. Relating to this, such a development of current therapy needs to find special biomarkers to characterise metabolic heterogeneity of gliomas.",
keywords = "Anti-metabolic drug combinations, Doxycycline, Glioblastoma, mTOR inhibitor, Rapamycin, Temozolomide, Tumour metabolism",
author = "G{\'a}bor Petov{\'a}ri and Zolt{\'a}n Hujber and Ildik{\'o} Krencz and Titanilla Dank{\'o} and No{\'e}mi Nagy and Fanni T{\'o}th and Regina Raffay and Katalin M{\'e}sz{\'a}ros and Hajnalka Rajnai and Eniko Vetl{\'e}nyi and K. Tak{\'a}cs-Vellai and A. Jeney and A. Sebesty{\'e}n",
year = "2018",
month = "12",
day = "19",
doi = "10.1186/s12935-018-0710-0",
language = "English",
volume = "18",
journal = "Cancer Cell International",
issn = "1475-2867",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells

AU - Petovári, Gábor

AU - Hujber, Zoltán

AU - Krencz, Ildikó

AU - Dankó, Titanilla

AU - Nagy, Noémi

AU - Tóth, Fanni

AU - Raffay, Regina

AU - Mészáros, Katalin

AU - Rajnai, Hajnalka

AU - Vetlényi, Eniko

AU - Takács-Vellai, K.

AU - Jeney, A.

AU - Sebestyén, A.

PY - 2018/12/19

Y1 - 2018/12/19

N2 - Background: Glioma is the most common highly aggressive, primary adult brain tumour. Clinical data show that therapeutic approaches cannot reach the expectations in patients, thus gliomas are mainly incurable diseases. Tumour cells can adapt rapidly to alterations during therapeutic treatments related to their metabolic rewiring and profound heterogeneity in tissue environment. Renewed interests aim to develop effective treatments targeting angiogenesis, kinase activity and/or cellular metabolism. mTOR (mammalian target of rapamycin), whose hyper-activation is characteristic for many tumours, promotes metabolic alterations, macromolecule biosynthesis, cellular growth and survival. Unfortunately, mTOR inhibitors with their lower toxicity have not resulted in appreciable survival benefit. Analysing mTOR inhibitor sensitivity, other metabolism targeting treatments and their combinations could help to find potential agents and biomarkers for therapeutic development in glioma patients. Methods: In vitro proliferation assays, protein expression and metabolite concentration analyses were used to study the effects of mTOR inhibitors, other metabolic treatments and their combinations in glioma cell lines. Furthermore, mTOR activity and cellular metabolism related protein expression patterns were also investigated by immunohistochemistry in human biopsies. Temozolomide and/or rapamycin treatments altered the expressions of enzymes related to lipid synthesis, glycolysis and mitochondrial functions as consequences of metabolic adaptation; therefore, other anti-metabolic drugs (chloroquine, etomoxir, doxycycline) were combined in vitro. Results: Our results suggest that co-targeting metabolic pathways had tumour cell dependent additive/synergistic effects related to mTOR and metabolic protein expression patterns cell line dependently. Drug combinations, especially rapamycin + doxycycline may have promising anti-tumour effect in gliomas. Additionally, our immunohistochemistry results suggest that metabolic and mTOR activity alterations are not related to the recent glioma classification, and these protein expression profiles show individual differences in patients' materials. Conclusions: Based on these, combinations of different new/old drugs targeting cellular metabolism could be promising to inhibit high adaptation capacity of tumour cells depending on their metabolic shifts. Relating to this, such a development of current therapy needs to find special biomarkers to characterise metabolic heterogeneity of gliomas.

AB - Background: Glioma is the most common highly aggressive, primary adult brain tumour. Clinical data show that therapeutic approaches cannot reach the expectations in patients, thus gliomas are mainly incurable diseases. Tumour cells can adapt rapidly to alterations during therapeutic treatments related to their metabolic rewiring and profound heterogeneity in tissue environment. Renewed interests aim to develop effective treatments targeting angiogenesis, kinase activity and/or cellular metabolism. mTOR (mammalian target of rapamycin), whose hyper-activation is characteristic for many tumours, promotes metabolic alterations, macromolecule biosynthesis, cellular growth and survival. Unfortunately, mTOR inhibitors with their lower toxicity have not resulted in appreciable survival benefit. Analysing mTOR inhibitor sensitivity, other metabolism targeting treatments and their combinations could help to find potential agents and biomarkers for therapeutic development in glioma patients. Methods: In vitro proliferation assays, protein expression and metabolite concentration analyses were used to study the effects of mTOR inhibitors, other metabolic treatments and their combinations in glioma cell lines. Furthermore, mTOR activity and cellular metabolism related protein expression patterns were also investigated by immunohistochemistry in human biopsies. Temozolomide and/or rapamycin treatments altered the expressions of enzymes related to lipid synthesis, glycolysis and mitochondrial functions as consequences of metabolic adaptation; therefore, other anti-metabolic drugs (chloroquine, etomoxir, doxycycline) were combined in vitro. Results: Our results suggest that co-targeting metabolic pathways had tumour cell dependent additive/synergistic effects related to mTOR and metabolic protein expression patterns cell line dependently. Drug combinations, especially rapamycin + doxycycline may have promising anti-tumour effect in gliomas. Additionally, our immunohistochemistry results suggest that metabolic and mTOR activity alterations are not related to the recent glioma classification, and these protein expression profiles show individual differences in patients' materials. Conclusions: Based on these, combinations of different new/old drugs targeting cellular metabolism could be promising to inhibit high adaptation capacity of tumour cells depending on their metabolic shifts. Relating to this, such a development of current therapy needs to find special biomarkers to characterise metabolic heterogeneity of gliomas.

KW - Anti-metabolic drug combinations

KW - Doxycycline

KW - Glioblastoma

KW - mTOR inhibitor

KW - Rapamycin

KW - Temozolomide

KW - Tumour metabolism

UR - http://www.scopus.com/inward/record.url?scp=85058970842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058970842&partnerID=8YFLogxK

U2 - 10.1186/s12935-018-0710-0

DO - 10.1186/s12935-018-0710-0

M3 - Article

AN - SCOPUS:85058970842

VL - 18

JO - Cancer Cell International

JF - Cancer Cell International

SN - 1475-2867

IS - 1

M1 - 211

ER -